Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Last updated: October 24, 2025
Sponsor: Stanford University
Overall Status: Suspended

Phase

2

Condition

Brain Cancer

Neurofibromatosis

Gliomas

Treatment

[6,6-²H₂]-Glucose

Clinical Study ID

NCT06855628
IRB-77846
R01CA277832-02
  • Ages > 18
  • All Genders

Study Summary

The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Any participant that consents to entry into the Phase II BPM31510 parent study (BPM31510IV-11)

  • Women of childbearing potential must have a negative pregnancy test

  • Ability to understand and the willingness to provide written informed consent.

Exclusion

Exclusion Criteria:

  • Refuse to have an IV

  • Allergy to MRI contrasts

  • Diabetic patients who are taking insulin

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: [6,6-²H₂]-Glucose
Phase: 2
Study Start date:
January 30, 2025
Estimated Completion Date:
February 29, 2028

Connect with a study center

  • Stanford University

    Palo Alto, California 94305
    United States

    Site Not Available

  • Stanford University

    Palo Alto 5380748, California 5332921 94305
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.